PL2523661T3 - Inhibitory NKCC do leczenia autyzmu - Google Patents
Inhibitory NKCC do leczenia autyzmuInfo
- Publication number
- PL2523661T3 PL2523661T3 PL11700533T PL11700533T PL2523661T3 PL 2523661 T3 PL2523661 T3 PL 2523661T3 PL 11700533 T PL11700533 T PL 11700533T PL 11700533 T PL11700533 T PL 11700533T PL 2523661 T3 PL2523661 T3 PL 2523661T3
- Authority
- PL
- Poland
- Prior art keywords
- autism
- treatment
- nkcc
- inhibitors
- nkcc inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305047 | 2010-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2523661T3 true PL2523661T3 (pl) | 2017-09-29 |
Family
ID=42077420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11700533T PL2523661T3 (pl) | 2010-01-15 | 2011-01-13 | Inhibitory NKCC do leczenia autyzmu |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9415028B2 (pl) |
| EP (1) | EP2523661B1 (pl) |
| JP (1) | JP5914357B2 (pl) |
| CN (2) | CN102811716B (pl) |
| AU (1) | AU2011206574B2 (pl) |
| CA (1) | CA2786956C (pl) |
| CY (1) | CY1119167T1 (pl) |
| DK (1) | DK2523661T3 (pl) |
| ES (1) | ES2627914T3 (pl) |
| HR (1) | HRP20170836T1 (pl) |
| HU (1) | HUE034866T2 (pl) |
| LT (1) | LT2523661T (pl) |
| PL (1) | PL2523661T3 (pl) |
| PT (1) | PT2523661T (pl) |
| RS (1) | RS56080B1 (pl) |
| RU (1) | RU2583926C2 (pl) |
| SI (1) | SI2523661T1 (pl) |
| WO (1) | WO2011086126A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
| ES2668909T3 (es) | 2009-01-06 | 2018-05-23 | Galenagen, Llc | Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| PT2523661T (pt) | 2010-01-15 | 2017-06-21 | Inserm (Institut Nat De La Santé Et De La Rech Médicale) | Inibidores de nkcc para o tratamento de autismo |
| US20120252894A1 (en) * | 2011-04-01 | 2012-10-04 | Giniatullin Rashid | Compounds for alleviating pain and stress in fetus and newborn |
| CN106310242B (zh) | 2011-04-21 | 2020-02-28 | 柯尔马克有限责任公司 | 用于治疗神经精神障碍的化合物 |
| CN104144698A (zh) * | 2012-01-03 | 2014-11-12 | 柯尔马克有限责任公司 | 治疗神经和精神障碍的行为症状的方法 |
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| JP6382232B2 (ja) * | 2013-02-21 | 2018-08-29 | ユニバ−シティ オブ ロチェスタ− | 脳全体の傍血管経路を老廃物のクリアランス機能について評価するための方法、およびそれに基づいて神経変性障害を治療するための方法 |
| JP6490077B2 (ja) | 2013-12-20 | 2019-03-27 | フォンダツィオーネ・イスティトゥート・イタリアーノ・ディ・テクノロジャＦｏｎｄａｚｉｏｎｅ Ｉｓｔｉｔｕｔｏ Ｉｔａｌｉａｎｏ Ｄｉ Ｔｅｃｎｏｌｏｇｉａ | ダウン症を治療するための細胞内塩化物濃度のモジュレータ |
| US10525024B2 (en) * | 2014-08-15 | 2020-01-07 | The Johns Hopkins University | Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290 |
| PT3297644T (pt) * | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| RU2633480C1 (ru) * | 2016-09-15 | 2017-10-12 | Александр Борисович Полетаев | Средство для стимуляции когнитивных функций при аутизме у детей |
| WO2018191233A1 (en) | 2017-04-10 | 2018-10-18 | Curemark, Llc | Compositions for treating addiction |
| EP3388520A1 (en) * | 2017-04-11 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof |
| CN111328284A (zh) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于维持和恢复健康的肠道屏障的组合物和方法 |
| CA3023014C (en) | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| AU2019274481A1 (en) * | 2018-05-25 | 2020-12-03 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
| WO2020016160A1 (en) | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| CN110684775A (zh) * | 2019-07-01 | 2020-01-14 | 上海海洋大学 | 一种中华绒螯蟹nkcc基因及其克隆方法和表达分析方法 |
| AU2020316330A1 (en) | 2019-07-19 | 2022-01-06 | Finch Therapeutics Holdings Llc. | Methods and products for treatment of gastrointestinal disorders |
| WO2021084120A1 (en) | 2019-10-31 | 2021-05-06 | Neurochlore | Liquid oral formulation of bumetanide |
| EP4069222A4 (en) | 2019-12-04 | 2023-12-27 | Resq Pharmaceuticals LLC | METHODS AND COMPOSITIONS FOR TREATING EDEMA NOT RESPONSIVE TO ORAL DIURETICS |
| EP3881842A1 (en) * | 2020-03-19 | 2021-09-22 | Stalicla S.A. | Compositions for the treatment of autism spectrum disorder |
| EP4175626A4 (en) * | 2020-07-01 | 2024-07-17 | Neuropro Therapeutics, Inc. | NEW PHARMACEUTICAL COMPOSITIONS |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985777A (en) | 1968-12-24 | 1976-10-12 | Lovens Kemiske Fabrik Produktionsaktieselskab | Sulphamyl-benzoic acid derivatives |
| US4247550A (en) | 1975-07-08 | 1981-01-27 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Compositions and methods for the treatment of hypertension or oedemas |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB2207129A (en) | 1987-07-13 | 1989-01-25 | Leo Pharm Prod Ltd | N-(1-carboxy-3-phenylpropyl)alanyl derivatives |
| CA2084987C (en) | 1990-06-11 | 2007-02-13 | Gilead Sciences, Inc. | Nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| JP2007504135A (ja) | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| JP2008535836A (ja) * | 2005-04-07 | 2008-09-04 | ニューロセラピューティクス ファーマ エルエルシー | 不安障害の治療のための方法および組成物 |
| EP1968603A4 (en) | 2006-01-03 | 2013-01-16 | Algebra Inc | THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS |
| EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| CL2009000294A1 (es) | 2008-02-08 | 2009-10-23 | Shlorion Pharma Inc | Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion. |
| WO2009114950A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| CN102341380A (zh) * | 2009-01-22 | 2012-02-01 | 神经病治疗药物股份有限公司 | 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法 |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| PT2523661T (pt) | 2010-01-15 | 2017-06-21 | Inserm (Institut Nat De La Santé Et De La Rech Médicale) | Inibidores de nkcc para o tratamento de autismo |
| JP2013536178A (ja) | 2010-07-26 | 2013-09-19 | ニューロセラピューティクス ファーマ， インコーポレイテッド | アリールスルホンアミド誘導体、組成物、および使用方法 |
-
2011
- 2011-01-13 PT PT117005330T patent/PT2523661T/pt unknown
- 2011-01-13 RU RU2012133067/15A patent/RU2583926C2/ru active
- 2011-01-13 RS RS20170570A patent/RS56080B1/sr unknown
- 2011-01-13 JP JP2012548435A patent/JP5914357B2/ja not_active Expired - Fee Related
- 2011-01-13 PL PL11700533T patent/PL2523661T3/pl unknown
- 2011-01-13 WO PCT/EP2011/050394 patent/WO2011086126A1/en not_active Ceased
- 2011-01-13 HR HRP20170836TT patent/HRP20170836T1/hr unknown
- 2011-01-13 DK DK11700533.0T patent/DK2523661T3/en active
- 2011-01-13 HU HUE11700533A patent/HUE034866T2/hu unknown
- 2011-01-13 CN CN201180014118.4A patent/CN102811716B/zh not_active Expired - Fee Related
- 2011-01-13 LT LTEP11700533.0T patent/LT2523661T/lt unknown
- 2011-01-13 CA CA2786956A patent/CA2786956C/en active Active
- 2011-01-13 ES ES11700533.0T patent/ES2627914T3/es active Active
- 2011-01-13 CN CN201710695535.9A patent/CN107595828A/zh active Pending
- 2011-01-13 US US13/522,372 patent/US9415028B2/en active Active
- 2011-01-13 AU AU2011206574A patent/AU2011206574B2/en not_active Ceased
- 2011-01-13 SI SI201131203T patent/SI2523661T1/sl unknown
- 2011-01-13 EP EP11700533.0A patent/EP2523661B1/en active Active
-
2013
- 2013-11-22 US US14/087,244 patent/US9592214B2/en not_active Expired - Fee Related
-
2017
- 2017-06-08 CY CY20171100608T patent/CY1119167T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1119167T1 (el) | 2018-02-14 |
| EP2523661B1 (en) | 2017-05-10 |
| CA2786956A1 (en) | 2011-07-21 |
| RU2012133067A (ru) | 2014-02-20 |
| HRP20170836T1 (hr) | 2017-09-08 |
| US9415028B2 (en) | 2016-08-16 |
| US20130022622A1 (en) | 2013-01-24 |
| HUE034866T2 (hu) | 2018-03-28 |
| WO2011086126A1 (en) | 2011-07-21 |
| EP2523661A1 (en) | 2012-11-21 |
| CN107595828A (zh) | 2018-01-19 |
| CN102811716A (zh) | 2012-12-05 |
| RS56080B1 (sr) | 2017-10-31 |
| SI2523661T1 (sl) | 2017-09-29 |
| ES2627914T3 (es) | 2017-08-01 |
| AU2011206574A1 (en) | 2012-08-09 |
| PT2523661T (pt) | 2017-06-21 |
| DK2523661T3 (en) | 2017-07-03 |
| JP2013517251A (ja) | 2013-05-16 |
| LT2523661T (lt) | 2017-08-10 |
| AU2011206574B2 (en) | 2015-01-22 |
| JP5914357B2 (ja) | 2016-05-11 |
| CA2786956C (en) | 2018-07-10 |
| US9592214B2 (en) | 2017-03-14 |
| RU2583926C2 (ru) | 2016-05-10 |
| CN102811716B (zh) | 2017-08-25 |
| US20140080910A1 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2523661T3 (pl) | Inhibitory NKCC do leczenia autyzmu | |
| PL2927213T3 (pl) | Pochodne piperydynonu jako inhibitory MDM2 do leczenia nowotworu | |
| PL2753334T3 (pl) | Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych | |
| EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
| EP2928471A4 (en) | HISTONDEMETHYLASE INHIBITORS | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| PL3513793T3 (pl) | Heterocykloaminy jako inhibitory pi3k | |
| EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
| EP2740419A4 (en) | TREATMENT INSTRUMENT | |
| PL3459942T3 (pl) | Inhibitory DNA-PK | |
| HUE039506T2 (hu) | Ibat inhibitorok májbetegségek kezelésére | |
| HRP20180237T1 (hr) | Metode za liječenje hcv-a | |
| DK3251678T3 (da) | Benzoxaborolderivater til behandling af bakterieinfektioner | |
| PL2822930T3 (pl) | Inhibitory beta-sekretazy | |
| BR112013025761A2 (pt) | inibidores de hsp90 | |
| EP2579936A4 (en) | INTRAGASTRIC DEVICE FOR TREATING OBESITY | |
| LT2928477T (lt) | Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui | |
| IL228719A0 (en) | parp inhibitors for the treatment of cipn | |
| HUE063599T2 (hu) | Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére | |
| EP2413941A4 (en) | Renin Inhibitors | |
| EP2750709A4 (en) | TREATMENT OF KACHEXIE | |
| EP2933248A4 (en) | NOVEL RENIN INHIBITOR | |
| EP2718255A4 (en) | QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES | |
| EP2858975A4 (en) | FBXO3 INHIBITORS |